Viyash Scientific Ltd
Viyash Scientific Ltd Q2 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
SeQuent Scientific aims for sustained double-digit revenue growth, targeting around 15% year-on-year, as demonstrated by recent quarters. Revenue Growth**: SeQuent expects strong top-line growth with a 15% YoY increase in Q2 FY26 revenue; Viyash anticipates over 20% CAGR in the next 3 years.
From Viyash Scientific Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- SeQuent Scientific aims for sustained double-digit revenue growth, targeting around 15% year-on-year, as demonstrated by recent quarters.
- Formulation segment is expected to grow strongly, particularly in companion animal health, with plans to expand front-end presence in markets like Mexico and launch new products in Latin America (e.g., tulathromycin injection in Brazil).
- API business targets maintaining an INR100 crore run rate with growth expected from FY '27 onwards, supported by new production lines and increased capacity (e.g., albendazole sales growing due to site shutdowns of competitors).
- The combined entity post-merger expects robust growth driven by synergies in R&D, manufacturing optimization, and product launches, aiming for at least 20% EBITDA margin sustainability.
- CDMO (Contract Development and Manufacturing Organization) business, which lagged earlier, is expected to recover and grow substantially over the next 2 years.
- The company is also focused on higher-value product mix improvements to drive better margins alongside revenue growth.
Profitability & Margins
See what Viyash Scientific Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Capex for API segment:
- - Around INR 60 crores spent recently by Viyash.
- - No major capex expected in the next 2 years for current strategic API business.
- - Some capex might be required for new opportunities like CDMO and complex molecules.
- Capex for formulation segment:
- - Planning to improve pet care manufacturing capability starting possibly from FY '27, spilling into FY '28.
- - Expected capex of about INR 100-150 crores in FY '27-FY '28 focused on manufacturing base, predominantly in India.
- Strategic investments:
- - Actively exploring inorganic opportunities—both small and large—that fit the global animal health strategy.
- - Inorganic targets include front-end expansion in Europe, new product in-licensing, manufacturing base expansion in India.
- - Aim to fill capability gaps and expand global animal health footprint.
- Debt reduction expected by FY '27 unless impacted by inorganic deals.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Viyash Scientific Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Viyash Scientific Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹920 Cr, net profit ₹66 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Viyash Scientific Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q1 FY26 earnings call →
- Q4 FY25 earnings call →
- Q3 FY25 earnings call →
- Q2 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Alivus Life Sciences Ltd (Q2 FY26)
Capex for H1 FY '26 was INR113 crores; Q2 alone INR61 crores. Key concall takeaways from Alivus Life's Q2 FY26 earnings call — and how it ranks against sector…
- Solara Active Pharma Sciences Ltd (Q2 FY26)
Current facility capacity utilization is about 70%, with capacity available to serve new customers. Key concall takeaways from Solara Active's Q2 FY26 earnings…
- Sun Pharmaceutical Industries Ltd (Q2 FY26)
India formulation sales grew 11% in Q2, outpacing Indian Pharmaceutical Market (IPM) growth mainly driven by volume and new product launches. Key concall…
- Zydus Lifesciences Ltd (Q2 FY26)
Branded formulations in India growing ahead of market at 9% YoY, driven by chronic, cardiology, gynecology, and oncology therapies. Key concall takeaways from…
Frequently Asked Questions
What were Viyash Scientific Ltd Q2 FY26 results?
SeQuent Scientific aims for sustained double-digit revenue growth, targeting around 15% year-on-year, as demonstrated by recent quarters. Revenue Growth**: SeQuent expects strong top-line growth with a 15% YoY increase in Q2 FY26 revenue; Viyash anticipates over 20% CAGR in the next 3 years.
What is Viyash Scientific Ltd share price analysis?
Viyash Scientific Ltd currently shows a neutral. The stock trades at a P/E of 50.8 with a market cap of ₹11,246 Cr. Investors should review the full earnings analysis for detailed insights.
Is Viyash Scientific Ltd planning capital expenditure?
Capex for API segment: - Around INR 60 crores spent recently by Viyash.
Keep Viyash Scientific Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.